Pharm HESI Exam • HESI • Elsevier Assessment • 2026/2027
UPDATED FOR 2026/2027 • HESI BLUEPRINT
PHARM HESI EXAM
NURSING PHARMACOLOGY SPECIALTY EXAMINATION
EXAM • 2026/2027 • 205 QUESTIONS
Realistic Practice Questions and Correct Answers with Detailed Rationales,
Verified Regulatory Citations, and Distractor Analysis for Every Item
205 VERIFIED Q&As Randomized Choice Order Updated for 2026/2027 Full Rationales
Overview
This comprehensive study guide provides 205 unique practice questions built for nursing students
preparing for the HESI Pharmacology specialty examination for 2026/2027. Every item is aligned
to FDA prescribing information and boxed warnings at 21 CFR 201.57, DEA controlled substance
scheduling at 21 CFR 1308, USP compounding and dosage form standards, the Joint Commission
National Patient Safety Goals, and state nurse practice act standards for safe medication
administration. Each question includes a regulatory or clinical citation, a written rationale, and a
full distractor analysis explaining why every incorrect option fails.
A note on the testing authority: HESI, Health Education Systems Incorporated, is an assessment publisher
acquired by Elsevier in 2006. It is not a certifying, licensing, or regulating body and it issues no credential. HESI
exams are standardized assessments that nursing programs administer internally to measure content mastery
and to predict readiness for the NCLEX, which is the actual licensure examination, developed by the NCSBN and
required by state boards of nursing. HESI does not publish the regulations tested here. The clinical and legal
authorities that actually govern the answers in this bank are the FDA, the DEA, USP, the Joint Commission, OSHA,
and state nurse practice acts, and every citation points to the source that governs that specific answer.
✓ KEY FEATURES
• 205 unique, verified questions with zero duplicate stems
• Randomized correct-answer placement across all four letters, verified by distribution audit
• Citations to FDA labeling and boxed warnings, DEA 21 CFR 1308, USP standards, and Joint
Commission NPSGs
• Real clinical values: therapeutic drug levels, INR targets, antidotes, insulin onset and peak, and
safe dose ranges
• Detailed rationale plus per-option distractor analysis for every item
• Master Quick Answer Key with compact grid layout and duplicate-check confirmation
1 | HESI • Elsevier Assessment
, Pharm HESI Exam • HESI • Elsevier Assessment • 2026/2027
▣ CORE CONTENT AREAS
• Section 1: Pharmacokinetics & Pharmacodynamics — 30 questions
• Section 2: Medication Administration & Safety — 35 questions
• Section 3: Cardiovascular, Renal & Hematologic Drugs — 30 questions
• Section 4: Neurologic, Psychiatric & Pain Medications — 30 questions
• Section 5: Antibiotics, Antivirals & Antifungals — 25 questions
• Section 6: Endocrine, GI, Respiratory & Immune Drugs — 25 questions
• Section 7: Pharmacological Nursing Considerations & Special Populations — 30
questions
2 | HESI • Elsevier Assessment
, Pharm HESI Exam • HESI • Elsevier Assessment • 2026/2027
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (30
QUESTIONS)
Absorption, distribution, metabolism, excretion, receptor binding, dose-response, and therapeutic index
1. Pharmacokinetics is best defined as:
A. What the drug does to the body at the receptor level
B. The study of drug costs and formulary placement
C. The legal classification of controlled substances
D. What the body does to the drug, including absorption, distribution, metabolism, and
excretion
Correct Answer: D. What the body does to the drug, including absorption, distribution,
metabolism, and excretion
Standard pharmacology principles; FDA labeling 21 CFR 201.57
Rationale: Pharmacodynamics is the reciprocal concept describing the drug's effect on the body.
Distractor Analysis:
A is incorrect: "What the drug does to the body at the receptor level" — violates Standard pharmacology
principles; FDA labeling 21 CFR 201.57 and would breach scope/safety vs correct practice.
B is incorrect: "The study of drug costs and formulary placement" — violates Standard pharmacology
principles; FDA labeling 21 CFR 201.57 and would breach scope/safety vs correct practice.
C is incorrect: "The legal classification of controlled substances" — violates Standard pharmacology
principles; FDA labeling 21 CFR 201.57 and would breach scope/safety vs correct practice.
2. The four processes of pharmacokinetics in sequence are:
A. Ingestion, digestion, circulation, elimination
B. Binding, activation, inhibition, clearance
C. Absorption, distribution, metabolism, excretion
D. Onset, peak, duration, withdrawal
Correct Answer: C. Absorption, distribution, metabolism, excretion
Standard pharmacology principles
Rationale: Each phase can be independently altered by disease, age, or interacting drugs.
Distractor Analysis:
A is incorrect: "Ingestion, digestion, circulation, elimination" — violates Standard pharmacology principles
and would breach scope/safety vs correct practice.
B is incorrect: "Binding, activation, inhibition, clearance" — violates Standard pharmacology principles
and would breach scope/safety vs correct practice.
D is incorrect: "Onset, peak, duration, withdrawal" — violates Standard pharmacology principles and
would breach scope/safety vs correct practice.
3 | HESI • Elsevier Assessment
, Pharm HESI Exam • HESI • Elsevier Assessment • 2026/2027
3. Bioavailability refers to:
A. The total dose prescribed
B. The fraction of an administered dose that reaches systemic circulation unchanged
C. The rate of renal excretion
D. The drug's affinity for its receptor
Correct Answer: B. The fraction of an administered dose that reaches systemic circulation
unchanged
FDA 21 CFR 320.1 bioavailability definition
Rationale: Intravenous administration is 100 percent bioavailable because it bypasses absorption entirely.
Distractor Analysis:
A is incorrect: "The total dose prescribed" — violates FDA 21 CFR 320.1 bioavailability definition and would
breach scope/safety vs correct practice.
C is incorrect: "The rate of renal excretion" — violates FDA 21 CFR 320.1 bioavailability definition and
would breach scope/safety vs correct practice.
D is incorrect: "The drug's affinity for its receptor" — violates FDA 21 CFR 320.1 bioavailability definition
and would breach scope/safety vs correct practice.
4. The first-pass effect refers to:
A. The first dose producing the greatest effect
B. Initial distribution to the brain
C. Hepatic metabolism of an oral drug before it reaches systemic circulation
D. The first sign of an adverse reaction
Correct Answer: C. Hepatic metabolism of an oral drug before it reaches systemic circulation
Standard pharmacology principles
Rationale: Drugs with extensive first-pass metabolism require higher oral doses than parenteral doses.
Distractor Analysis:
A is incorrect: "The first dose producing the greatest effect" — violates Standard pharmacology principles
and would breach scope/safety vs correct practice.
B is incorrect: "Initial distribution to the brain" — violates Standard pharmacology principles and would
breach scope/safety vs correct practice.
D is incorrect: "The first sign of an adverse reaction" — violates Standard pharmacology principles and
would breach scope/safety vs correct practice.
5. Which route completely bypasses the first-pass effect?
A. Oral
B. Intravenous
C. Enteral via nasogastric tube
D. Rectal, completely
Correct Answer: B. Intravenous
Standard pharmacology principles
Rationale: Rectal administration only partially bypasses the liver, as some venous drainage reaches the portal
system.
Distractor Analysis:
A is incorrect: "Oral" — violates Standard pharmacology principles and would breach scope/safety vs
correct practice.
C is incorrect: "Enteral via nasogastric tube" — violates Standard pharmacology principles and would
breach scope/safety vs correct practice.
4 | HESI • Elsevier Assessment
UPDATED FOR 2026/2027 • HESI BLUEPRINT
PHARM HESI EXAM
NURSING PHARMACOLOGY SPECIALTY EXAMINATION
EXAM • 2026/2027 • 205 QUESTIONS
Realistic Practice Questions and Correct Answers with Detailed Rationales,
Verified Regulatory Citations, and Distractor Analysis for Every Item
205 VERIFIED Q&As Randomized Choice Order Updated for 2026/2027 Full Rationales
Overview
This comprehensive study guide provides 205 unique practice questions built for nursing students
preparing for the HESI Pharmacology specialty examination for 2026/2027. Every item is aligned
to FDA prescribing information and boxed warnings at 21 CFR 201.57, DEA controlled substance
scheduling at 21 CFR 1308, USP compounding and dosage form standards, the Joint Commission
National Patient Safety Goals, and state nurse practice act standards for safe medication
administration. Each question includes a regulatory or clinical citation, a written rationale, and a
full distractor analysis explaining why every incorrect option fails.
A note on the testing authority: HESI, Health Education Systems Incorporated, is an assessment publisher
acquired by Elsevier in 2006. It is not a certifying, licensing, or regulating body and it issues no credential. HESI
exams are standardized assessments that nursing programs administer internally to measure content mastery
and to predict readiness for the NCLEX, which is the actual licensure examination, developed by the NCSBN and
required by state boards of nursing. HESI does not publish the regulations tested here. The clinical and legal
authorities that actually govern the answers in this bank are the FDA, the DEA, USP, the Joint Commission, OSHA,
and state nurse practice acts, and every citation points to the source that governs that specific answer.
✓ KEY FEATURES
• 205 unique, verified questions with zero duplicate stems
• Randomized correct-answer placement across all four letters, verified by distribution audit
• Citations to FDA labeling and boxed warnings, DEA 21 CFR 1308, USP standards, and Joint
Commission NPSGs
• Real clinical values: therapeutic drug levels, INR targets, antidotes, insulin onset and peak, and
safe dose ranges
• Detailed rationale plus per-option distractor analysis for every item
• Master Quick Answer Key with compact grid layout and duplicate-check confirmation
1 | HESI • Elsevier Assessment
, Pharm HESI Exam • HESI • Elsevier Assessment • 2026/2027
▣ CORE CONTENT AREAS
• Section 1: Pharmacokinetics & Pharmacodynamics — 30 questions
• Section 2: Medication Administration & Safety — 35 questions
• Section 3: Cardiovascular, Renal & Hematologic Drugs — 30 questions
• Section 4: Neurologic, Psychiatric & Pain Medications — 30 questions
• Section 5: Antibiotics, Antivirals & Antifungals — 25 questions
• Section 6: Endocrine, GI, Respiratory & Immune Drugs — 25 questions
• Section 7: Pharmacological Nursing Considerations & Special Populations — 30
questions
2 | HESI • Elsevier Assessment
, Pharm HESI Exam • HESI • Elsevier Assessment • 2026/2027
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (30
QUESTIONS)
Absorption, distribution, metabolism, excretion, receptor binding, dose-response, and therapeutic index
1. Pharmacokinetics is best defined as:
A. What the drug does to the body at the receptor level
B. The study of drug costs and formulary placement
C. The legal classification of controlled substances
D. What the body does to the drug, including absorption, distribution, metabolism, and
excretion
Correct Answer: D. What the body does to the drug, including absorption, distribution,
metabolism, and excretion
Standard pharmacology principles; FDA labeling 21 CFR 201.57
Rationale: Pharmacodynamics is the reciprocal concept describing the drug's effect on the body.
Distractor Analysis:
A is incorrect: "What the drug does to the body at the receptor level" — violates Standard pharmacology
principles; FDA labeling 21 CFR 201.57 and would breach scope/safety vs correct practice.
B is incorrect: "The study of drug costs and formulary placement" — violates Standard pharmacology
principles; FDA labeling 21 CFR 201.57 and would breach scope/safety vs correct practice.
C is incorrect: "The legal classification of controlled substances" — violates Standard pharmacology
principles; FDA labeling 21 CFR 201.57 and would breach scope/safety vs correct practice.
2. The four processes of pharmacokinetics in sequence are:
A. Ingestion, digestion, circulation, elimination
B. Binding, activation, inhibition, clearance
C. Absorption, distribution, metabolism, excretion
D. Onset, peak, duration, withdrawal
Correct Answer: C. Absorption, distribution, metabolism, excretion
Standard pharmacology principles
Rationale: Each phase can be independently altered by disease, age, or interacting drugs.
Distractor Analysis:
A is incorrect: "Ingestion, digestion, circulation, elimination" — violates Standard pharmacology principles
and would breach scope/safety vs correct practice.
B is incorrect: "Binding, activation, inhibition, clearance" — violates Standard pharmacology principles
and would breach scope/safety vs correct practice.
D is incorrect: "Onset, peak, duration, withdrawal" — violates Standard pharmacology principles and
would breach scope/safety vs correct practice.
3 | HESI • Elsevier Assessment
, Pharm HESI Exam • HESI • Elsevier Assessment • 2026/2027
3. Bioavailability refers to:
A. The total dose prescribed
B. The fraction of an administered dose that reaches systemic circulation unchanged
C. The rate of renal excretion
D. The drug's affinity for its receptor
Correct Answer: B. The fraction of an administered dose that reaches systemic circulation
unchanged
FDA 21 CFR 320.1 bioavailability definition
Rationale: Intravenous administration is 100 percent bioavailable because it bypasses absorption entirely.
Distractor Analysis:
A is incorrect: "The total dose prescribed" — violates FDA 21 CFR 320.1 bioavailability definition and would
breach scope/safety vs correct practice.
C is incorrect: "The rate of renal excretion" — violates FDA 21 CFR 320.1 bioavailability definition and
would breach scope/safety vs correct practice.
D is incorrect: "The drug's affinity for its receptor" — violates FDA 21 CFR 320.1 bioavailability definition
and would breach scope/safety vs correct practice.
4. The first-pass effect refers to:
A. The first dose producing the greatest effect
B. Initial distribution to the brain
C. Hepatic metabolism of an oral drug before it reaches systemic circulation
D. The first sign of an adverse reaction
Correct Answer: C. Hepatic metabolism of an oral drug before it reaches systemic circulation
Standard pharmacology principles
Rationale: Drugs with extensive first-pass metabolism require higher oral doses than parenteral doses.
Distractor Analysis:
A is incorrect: "The first dose producing the greatest effect" — violates Standard pharmacology principles
and would breach scope/safety vs correct practice.
B is incorrect: "Initial distribution to the brain" — violates Standard pharmacology principles and would
breach scope/safety vs correct practice.
D is incorrect: "The first sign of an adverse reaction" — violates Standard pharmacology principles and
would breach scope/safety vs correct practice.
5. Which route completely bypasses the first-pass effect?
A. Oral
B. Intravenous
C. Enteral via nasogastric tube
D. Rectal, completely
Correct Answer: B. Intravenous
Standard pharmacology principles
Rationale: Rectal administration only partially bypasses the liver, as some venous drainage reaches the portal
system.
Distractor Analysis:
A is incorrect: "Oral" — violates Standard pharmacology principles and would breach scope/safety vs
correct practice.
C is incorrect: "Enteral via nasogastric tube" — violates Standard pharmacology principles and would
breach scope/safety vs correct practice.
4 | HESI • Elsevier Assessment
